(Q48178091)

English

Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

author name string

Alison P Coletta

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

Andrew L Clark

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

publication date

3 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

European Journal of Heart Failure

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

9

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

6-7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

740-745

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

The heart failure revascularisation trial (HEART): rationale, design and methodology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Optimal medical therapy with or without PCI for stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Complexity of program and clinical outcomes of heart failure disease management incorporating specialist nurse-led heart failure clinics. A meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2007.04.004

21 January 2018

Identifiers

10.1016/J.EJHEART.2007.04.004

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

release_uvs5s444uzaczgyisaadmtv22q

1 reference

https://api.fatcat.wiki/v0/release/uvs5s444uzaczgyisaadmtv22q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/17481946

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48178091&oldid=2188701335"